Business Wire

GCCA

20.2.2024 13:31:29 CET | Business Wire | Press release

Share
Start-ups Challenged to Help Develop Carbon Capture Technology for Global Industry’s Push to Net Zero

A pioneering international programme, which brings together tech start-ups and leading manufacturers in the pursuit of net zero, has launched.

Innovandi Open Challenge 2024 is run by the Global Cement and Concrete Association (GCCA), the industry’s leading international body which is focused on helping the global cement industry reduce its emissions and ultimately achieve net zero concrete.

Applications are being encouraged from start-ups from around the world, interested in working on the development of carbon capture use and storage, for low carbon cement and concrete. Innovative technologies are sought, which include process integrated and end-of-pipe CO2 capture and use, and help prevent the carbon being emitted into the atmosphere.

This will be the 3rd Innovandi Open Challenge and builds on the success of previous years. The first challenge, in 2022, also focused on the development of carbon capture technology, and two start-ups have already gone to pilot stage. The 15 start-ups shortlisted in last year’s 2nd Innovandi Challenge, to work on the development of low carbon concrete, are currently in discussion with manufacturers about forming partnerships.

Claude Loréa, the GCCA’s Cement, Innovation and ESG Director, said: “Our industry is committed to achieving net zero and the development of carbon capture technology is a key part of that work. Our world leading Innovandi Open Challenge programme has already seen remarkable progress being made in just two years, with start-ups and our member companies working together. We’re looking forward to seeing what this year’s applicants can bring, to build on the extensive work that is already underway across the world.”

All GCCA members who account for 80% of global cement production capacity outside of China, and a number of leading Chinese manufacturers, have committed to reaching net zero, by 2050, through the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first global industry to set out such a detailed plan. The GCCA has also recently signed a ground-breaking agreement to work together on decarbonisation with the China Cement Association (CCA).

The development of new technologies is a key part of the industry’s roadmap to net zero, and carbon capture and storage technology is expected to account for around 36% of total emission reductions by 2050.

The industry’s first industrial-scale cement plant equipped with CO2 capture technology is scheduled to be mechanically completed at the Heidelberg Materials site in Brevik, Norway, by the end of 2024, with several more plants expected to open by 2030.

Thomas Guillot, Chief Executive of the GCCA, said: “We already know CCUS technology works, with pilots and projects underway across the world, but it’s crucial to see what other innovations are out there, beyond our industry, that could help accelerate our net zero mission.

“We encourage applications from start-ups around the globe to join us in the urgent fight to limit global warming. If you are a start up from Austria to Australia, from Brazil to Bangladesh, with an innovative idea or technology to further develop CCUS, then you should be applying.”

Jonathan Cool, CEO of Ultra High Materials, a start-up which participated in last year’s Open Challenge, encouraged others to apply: “The support, guidance, exposure to the GCCA membership and the facilitation of collaborative opportunities with GCCA members has been effective, efficient and it's made a beneficial impact for all of us. Given the option to do it all again, we certainly would.”

Start-ups interested in applying to the third Innovandi Open Challenge, can click here for more information. The deadline for applications is 15th April.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220364304/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye